GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Onward Medical NV (OTCPK:ONWRF) » Definitions » EBITDA Margin %

Onward Medical NV (Onward Medical NV) EBITDA Margin % : 0.00% (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Onward Medical NV EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Onward Medical NV's EBITDA for the six months ended in Dec. 2023 was $-16.93 Mil. Onward Medical NV's Revenue for the six months ended in Dec. 2023 was $0.00 Mil. Therefore, Onward Medical NV's EBITDA margin for the quarter that ended in Dec. 2023 was 0.00%.


Onward Medical NV EBITDA Margin % Historical Data

The historical data trend for Onward Medical NV's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Onward Medical NV EBITDA Margin % Chart

Onward Medical NV Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial - - - - -

Onward Medical NV Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Onward Medical NV's EBITDA Margin %

For the Biotechnology subindustry, Onward Medical NV's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Onward Medical NV's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Onward Medical NV's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Onward Medical NV's EBITDA Margin % falls into.



Onward Medical NV EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Onward Medical NV's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-37.047/0
= %

Onward Medical NV's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-16.926/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Onward Medical NV  (OTCPK:ONWRF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Onward Medical NV EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Onward Medical NV's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Onward Medical NV (Onward Medical NV) Business Description

Traded in Other Exchanges
Address
High Tech Campus 32, Noord-Braban, Eindhoven, NH, NLD, NL-5656 AE
Onward Medical NV is a medical technology company developing and commercializing therapies to enable functional recovery for people with spinal cord injury. It has developed two programmable neurostimulation platforms: an implantable system, ARCIM, and a non-invasive, transcutaneous system, ARCEX. The company has selected the United states and four European markets: Germany, France, the UK and the Netherlands to create a customer base.

Onward Medical NV (Onward Medical NV) Headlines

No Headlines